To evaluate the efficacy and safety of Honghua Xiaoyao tablets in the treatment of premenstrual syndrome, and the results were further analyzed and evaluated by target trial simulation (TTE) framework.
Age:18-40 years old (both ends included);
According to the 8th edition of "Obstetrics and Gynecology" (2014), patients diagnosed with premenstrual syndrome;
In accordance with the TCM syndrome differentiation standard of liver depression and qi stagnation.
those who were allergic to the ingredients and excipients of Honghua Xiaoyao tablet (exposure group);
In the non-exposed group, those receiving or planning to receive other targeted medications for PMS, such as serotonin reuptake inhibitors (SSRIs), hormones, etc.;
irregular menstrual cycle (menstrual cycle not within 28±7 days);
serious diseases of cardiovascular, cerebrovascular, hematopoietic system, liver and kidney, and malignant tumors;
Lianxin Wang
Lead sponsor
China Academy of Chinese Medical Sciences
Sponsor institution
Chaoyangmen Community Health Service Center of Dongcheng District in Beijing
Collaborator
Hepingli Community Health Service Center,Dongcheng District,Beijing
Collaborator